Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

May 29, 2015 11:06 PM ET

Healthcare Equipment and Supplies

Company Overview of Alcon, Inc.

Company Overview

Alcon, Inc. develops and manufactures eye care products for eye care professionals and their patients. It offers surgical products, which include technologies and devices for cataract, retinal, glaucoma, and refractive surgery; advanced technology intraocular lenses to treat cataracts and refractive errors, such as presbyopia and astigmatism; and advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery. The company also provides pharmaceutical products for elevated intraocular pressure caused by glaucoma; anti-inflammatories; anti-infective to aid in the treatment of bacterial infections and bacterial conjunctivitis; oph...

6201 South Freeway

Fort Worth, TX 76134-2001

United States

Founded in 1945

16,700 Employees





Key Executives for Alcon, Inc.

Chief Financial Officer
Chief Operating Officer and Executive Vice President
Region President of Latin America and Canada
Region President of Asia
Region President of United States
Compensation as of Fiscal Year 2014.

Alcon, Inc. Key Developments

Alcon Announces Encouraging Results from Papillary Conjunctivitis Study

Alcon, Inc. announced encouraging results from a new study with CLEAR CARE cleaning and disinfecting solution in patients with contact lens papillary conjunctivitis. This randomized, controlled, investigator-masked, parallel group, multi-site study was conducted in 128 symptomatic contact lens wearers with mild to severe investigator-related palpebral roughness who were habitually using a biguanide-preserved multi-purpose solution. The subjects who used CLEAR CARE Solution during the study showed a significant improvement in lid papillae and symptoms compared to the subjects in the biguanide-preserved multi-purpose solution control group.

Alcon Enhances ORA System and VERION Image Guided System

Alcon has unveiled new enhancements to both the ORA System and the VERION image guided system. The VerifEye+ Technology in the ORA System offers the following enhancements to the previous version: provides on demand information to assist in intraoperative decision making and delivers this information to the surgeon via a dynamic reticle visible through the right ocular; and this leads to a more efficient workflow and surgeon usability in the operating room. The 2.6 software in the VERION Image Guided System offers the following enhancements to the previous version: improved functionality and usability in the clinic, at the LenSx Laser and at the microscope in the operating room; compatibility with existing local area network (LAN) based networks configured to connect the VERION components and replace the USB as the primary data transfer process; remote accessibility to the VERION Reference Unit planner database; and upgraded LenStar import and integration with compatible electronic medical record systems (EMRs). The enhancements also include: VERION Quick Snap image capture at the measurement module for surgeons using VERION image-based guidance on astigmatism axis with imported LenStar or manually entered K values; and optical enhancement of the microscope-integrated display (MID) for surgeons in need of improved low light registration and tracking.

Alcon Receives FDA Approval of Pazeo(TM) Solution for Ocular Allergy Itch Relief

Alcon has received approval from the US Food and Drug Administration (FDA) of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7%, for the treatment of ocular itching associated with allergic conjunctivitis. Pazeo solution is dosed one drop daily, and was approved with efficacy data at 24 hours, post dose. Results from two Conjunctival Allergen Challenge clinical studies showed that Pazeo (olopatadine hydrochloride ophthalmic solution) 0.7%, demonstrated statistically significantly improved relief of ocular itching associated with allergic conjunctivitis at 24 hours post-treatment compared to olopatadine 0.2% (known as Pataday(R) solution). The safety profile of Pazeo solution is comparable to that of olopatadine 0.2%. In the two clinical studies, the most common adverse reactions occurred in 2 to 5% of patients treated with either Pazeo solution or a vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia and abnormal sensation in the eye.

Similar Private Companies By Industry

Company Name Region
Sager Precision Technologies, Inc. United States
Bridge Bioscience, Inc. United States
Sterling Critical Products, LLC United States
Healthonics, Inc. United States
Med-Depot, Inc. United States

Recent Private Companies Transactions

August 27, 2014
WaveTec Vision Systems, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Alcon, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at